CDK4 and breast cancer: This review also discusses emerging technologies, including circulating DNA and single-cell sequencing, as promising avenues for discovery.<h4>Conclusion</h4>NGS has revealed the genomic and transcriptomic diversity of breast cancer, identifying actionable alterations associated with chemotherapy response and resistance to therapies such as trastuzumab, TKIs, and CDK4/6 inhibitors.